Catapharma Group

What Catapharma Group does

Catapharma Group is a privately-held, India-based specialty chemical manufacturer specializing in liquid-phase catalytic hydrogenation and a defined portfolio of related transformations (oxidation, N- and O-alkylation, nitrosation, low-temperature nitration, esterification, ethoxylation). Founded in 1986 and headquartered in Nashik, Maharashtra, the company operates two manufacturing sites at Sinnar (Nashik) and Erandol (Jalgaon) and reports 160+ dedicated experts with 40+ years of chemistry and process expertise. Its product catalog spans ten chemical categories — piperazine derivatives, catechol derivatives, aliphatic amines, benzylamine derivatives, cyclen derivatives (including DOTA for MRI contrast agents), amino acids (including tranexamic acid derivatives), cyclohexylamine derivatives, toluidine derivatives, piperidine derivatives, and a basket of other intermediates — alongside a Custom Synthesis Services offering that uses pilot-plant capabilities to take customer-specific chemistries from lab to commercial scale. The company is also EcoVadis Bronze (2023), EU REACH, Halal, and Kosher certified, positioning it as a qualified supplier for regulated pharmaceutical and life-sciences buyers.

The business is B2B and sales-led, with all commercial activity routed through direct quote requests on the company website against lead times ranging from 1-3 weeks (Regular) to 4-6 weeks (Against Order) and longer for R&D / Pilot Plant engagements. Pricing is fully quote-based and not publicly disclosed, consistent with custom intermediate supply to enterprise buyers. Two revenue streams are evident: catalog pharmaceutical intermediate sales (treated as one-time product transactions in the source data) and Custom Synthesis Services (treated as professional services). Distribution is direct to enterprise accounts, with no channel intermediaries, supplying in drums, IBC tanks, and ISO tank packaging.

The company serves three vertical segments: pharmaceutical industry (primary, including API intermediates and synthesis building blocks), agrochemical industry (crop protection intermediates), and perfumery industry (aromatic fine chemicals). Its named customer roster includes global pharma majors — Pfizer, Sanofi Aventis, Sandoz, Viatris, Mylan — alongside leading Indian generic manufacturers (Cipla, Dr. Reddy's, Lupin, Glenmark, Macleods, Aurobindo, Piramal, Torrent, Alembic, Jubilant, MSN Labs, Neuland) and specialty chemical customers (Saltigo, Sumitomo, Cambrex, UBE Industries, Corden Pharma, SRF, Endura, DSM Firmenich, Olon). The company claims presence in 30+ countries across four continents.

Name

Catapharma Group

Legal name

Catapharma Group

Website

https://catapharma.com

Company type

Private

Founded year

1986

Operating status

Operating

Headcount range

11–50 employees

Short description

Catapharma Group is a privately-held, India-based specialty chemical manufacturer specializing in liquid-phase catalytic hydrogenation and related transformations, producing pharmaceutical, agrochemical, and perfumery intermediates from two Maharashtra manufacturing sites for global enterprise buyers.

Ownership category

akta.pro rank

Product category

Pharmaceutical Intermediates & Fine Chemicals Manufacturing

NAICS

Chemical Manufacturing (325), All Other Basic Organic Chemical Manufacturing (325199)

SIC

Medicinal Chemicals & Botanical Products (2833), Industrial Organic Chemicals (2860)

akta.pro primary industry

Custom Intermediates & Advanced Intermediates Manufacturing (HLAGAHAH)

akta.pro secondary industry

Generic APIs & Intermediates (Active Ingredients) (HLAIABAG)

Keywords

• Pharmaceutical intermediates
• Specialty chemicals manufacturing
• Catalytic hydrogenation services
• Custom synthesis intermediates
• Fine chemicals B2B

Headquarters

HQ city

Mumbai

HQ country

India

HQ region

Asia

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Personnel, Infrastructure, Technology or R&D, Marketing or Sales

Revenue model

1. Pharmaceutical Intermediates Sales: Sale of catalog specialty chemical intermediates across multiple categories including piperazine derivatives, catechol derivatives, aliphatic amines, benzylamine derivatives, cyclen derivatives, and amino acids to pharmaceutical, agrochemical, and perfumery customers
2. Custom Synthesis Services: Tailored synthesis services leveraging pilot plant capabilities for complex chemistries, supporting customer-specific requirements at various scales

Pricing tiers

Go-to-market motion1 record

Distribution channels2 records

Marketing channels3 records

Core offering

Catapharma Group manufactures and sells specialty chemical intermediates for pharmaceutical, agrochemical, and perfumery industries, organized across ten product categories including piperazine derivatives, catechol derivatives, aliphatic amines, benzylamine derivatives, cyclen derivatives, amino acids, cyclohexylamine derivatives, toluidine derivatives, piperidine derivatives, and other intermediates. The company also offers custom synthesis services using pilot plant capabilities to scale complex chemistries. Its core competency is liquid-phase catalytic hydrogenation and related chemical transformations, producing high-purity intermediates at two manufacturing sites in India.

Product overview

Catapharma Group is a specialty chemical manufacturer with 40+ years of expertise in liquid-phase catalytic hydrogenation and related transformations, supplying advanced pharmaceutical intermediates to customers worldwide. The company operates two manufacturing sites in India and serves customers in 30+ countries across four continents. Their product portfolio consists of ten major chemical categories: Piperazine Derivatives (30+ products), Catechol Derivatives, Aliphatic Amines, Benzylamine Derivatives, Cyclohexylamine Derivatives, Toluidine Derivatives, Cyclen Derivatives (including DOTA for MRI contrast agents), Piperidine Derivatives, Amino Acids (including Tranexamic Acid derivatives), and Other Intermediates. The company also offers Custom Synthesis Services for complex chemistries using their pilot plant capabilities. Core technical competencies include catalytic hydrogenation, oxidation, N-alkylation, O-alkylation, nitrosation, low-temperature nitration, esterification, and ethoxylation. Customers include major global pharmaceutical companies such as Cipla, Dr. Reddy's, Pfizer, Sanofi, Sandoz, Viatris, Lupin, and Glenmark.

Differentiator

Problem solved

Functional benefit

Products and services

• Piperazine Derivatives Substituted piperazine compounds and derivatives for pharmaceutical applications, including N-Methyl Piperazine, N,N'-Dimethyl Piperazine, 1-Amino-4-Methyl Piperazine, N-Cyclopentyl Piperazine, 1-Amino-4-Cyclopentyl Piperazine, N-Ethyl Piperazine, N-i-Propyl Piperazine, N-i-Butyl Piperazine, N-Cyclohexyl Piperazine, and N-(Hydroxyethyl) Piperazine, supplied as intermediates to pharmaceutical manufacturers.
• Catechol Derivatives Methylenedioxy and methoxy benzene compounds for agrochemical and perfumery applications, including 1,2-Methylenedioxy Benzene, Sesamol, Piperonal, Veratrole, and Helional, supplied to specialty chemical and fragrance manufacturers.
• Aliphatic Amines Primary, secondary, and tertiary amines for water treatment and catalysts, including N,N-Dimethyl-1,3-Propanediamine, N,N-Diisopropyl Ethylamine (DIPEA), and various alkoxypropylamines, supplied to industrial and chemical customers.
• Benzylamine Derivatives High-purity benzylamine derivatives for pharmaceutical synthesis, including N-Benzyl-Iso-Propylamine, N-Methyl Benzylamine, N,N-Dimethyl Benzylamine (BDMA), and N-Benzyl Ethanolamine, supplied as intermediates to pharmaceutical manufacturers.
• Cyclen Derivatives Macrocyclic tetraaza compounds used for MRI contrast agents and research applications, including 1,4,7,10-Tetraazacyclododecane (Cyclen), Tetrabenzyl Cyclen (TBC), and DOTA, supplied to pharmaceutical and research customers.
• Amino Acids Cyclohexane carboxylic acid derivatives and specialized amino acids, including trans-N-BOC-4-Amino Cyclohexane Carboxylic Acid, 4-(Aminomethyl) Cyclohexane Carboxylic Acid (Tranexamic Acid), and various stereoisomers, supplied as pharmaceutical intermediates.
• Cyclohexylamine Derivatives N-substituted cyclohexylamine compounds for pharmaceutical applications, including N-Methyl Cyclohexylamine and N-Ethyl Cyclohexylamine (Vulkacit HX), supplied as intermediates to pharmaceutical manufacturers.
• Toluidine Derivatives N-alkyl toluidine compounds for chemical synthesis, including N-Ethyl-m-Toluidine, N-Ethyl-o-Toluidine, N,N-Dimethyl-m-Toluidine, and N-Methyl-m-Toluidine, supplied as intermediates to chemical and pharmaceutical manufacturers.
• Piperidine Derivatives N-substituted piperidine compounds supplied as pharmaceutical intermediates, including N-Methyl Piperidine, N-Ethyl Piperidine, N-Amino Piperidine, and Ethyl Nipecotate.
• Other Intermediates Specialized chemical intermediates including N-Aminomorpholine, Benzhydrol, Diamino Naphthalenes, Dihydro isobenzofurans, and Cyclohexanediones for various pharmaceutical and chemical applications.
• Custom Synthesis Services Tailored synthesis services that leverage pilot plant capabilities to scale complex chemistries beyond the catalog portfolio, supporting customer-specific requirements at various scales for pharmaceutical, agrochemical, and perfumery customers.

Quantifiable outcome

• 40+ years of continuous operation in specialty chemical manufacturing
• +2 more outcomes

Named customers26 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Scale indicators4 records

Recent moves4 records

Expansion highlights5 records

Broad incumbents

• Sumitomo Chemical: Diversified Japanese chemical company with specialty intermediates across pharma and agro. Broader portfolio but overlapping chemistries, and listed as a Catapharma customer.
• Aurobindo Pharma: Large Indian generics manufacturer with vertically integrated intermediates and API capabilities. Competes on intermediates supply and is also a Catapharma customer, operating at meaningfully larger scale.

Direct peers

• Neuland Laboratories: Indian CDMO focused on API intermediates and custom synthesis for global pharma, including complex chemistries analogous to Catapharma's hydrogenation and alkylation portfolio. Strong overlap in customer base and product positioning.
• Hikal Ltd: Indian specialty chemicals and intermediates manufacturer serving pharma, agro, and animal health. Comparable scale, geography, and product portfolio breadth.
• Divi's Laboratories: Indian API and intermediates manufacturer with deep custom synthesis capability supplying global generics and innovators. Closest comparable on geography, customer mix (large generics + innovators), and intermediates-led business model.
• Saltigo (Lanxess): Custom synthesis subsidiary of Lanxess specializing in complex organic intermediates for agro, pharma, and specialty chemicals. Directly comparable in custom synthesis positioning and is listed as a Catapharma customer.
• Piramal Pharma Solutions: Global CDMO with API intermediates and custom synthesis across multiple therapeutic categories. Directly comparable on offering breadth and B2B pharma customer model.
• Cambrex: API and custom synthesis manufacturer (acquired by Permira) serving global pharma with intermediates and drug substance capabilities. Mirrors Catapharma's enterprise customer model and is also listed as a customer of Catapharma.
• Sai Life Sciences: Indian CDMO offering API intermediates, custom synthesis, and process development for innovator and generic pharma. Comparable scale and chemistry scope including hydrogenation and complex transformations.
• Jubilant Pharmova: Indian CDMO and intermediates manufacturer (formerly Jubilant Life Sciences) supplying global pharma. Operates overlapping hydrogenation, alkylation, and custom synthesis capabilities and is also a named customer of Catapharma.

Market position

Strengths1 record

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Catapharma Group